- Home
- MLR vs CGEM Comparison
MLR vs CGEM Comparison
Compare MLR & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLR
- CGEM
- Stock Information
- Founded
- MLR 1990
- CGEM 2016
- Country
- MLR United States
- CGEM United States
- Employees
- MLR N/A
- CGEM N/A
- Industry
- MLR Construction/Ag Equipment/Trucks
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- MLR Consumer Discretionary
- CGEM Health Care
- Exchange
- MLR Nasdaq
- CGEM Nasdaq
- Market Cap
- MLR 769.3M
- CGEM 730.2M
- IPO Year
- MLR 1994
- CGEM 2021
- Fundamental
- Price
- MLR $67.91
- CGEM $10.26
- Analyst Decision
- MLR Strong Buy
- CGEM Strong Buy
- Analyst Count
- MLR 1
- CGEM 7
- Target Price
- MLR $82.00
- CGEM $31.67
- AVG Volume (30 Days)
- MLR 72.5K
- CGEM 614.7K
- Earning Date
- MLR 03-05-2025
- CGEM 03-13-2025
- Dividend Yield
- MLR 1.12%
- CGEM N/A
- EPS Growth
- MLR 35.81
- CGEM N/A
- EPS
- MLR 6.02
- CGEM N/A
- Revenue
- MLR $1,331,839,000.00
- CGEM N/A
- Revenue This Year
- MLR $16.10
- CGEM N/A
- Revenue Next Year
- MLR $6.72
- CGEM N/A
- P/E Ratio
- MLR $11.28
- CGEM N/A
- Revenue Growth
- MLR 22.98
- CGEM N/A
- 52 Week Low
- MLR $38.61
- CGEM $9.50
- 52 Week High
- MLR $78.25
- CGEM $30.19
- Technical
- Relative Strength Index (RSI)
- MLR 52.25
- CGEM 34.25
- Support Level
- MLR $62.25
- CGEM $9.50
- Resistance Level
- MLR $67.77
- CGEM $11.31
- Average True Range (ATR)
- MLR 1.59
- CGEM 0.77
- MACD
- MLR 0.37
- CGEM -0.11
- Stochastic Oscillator
- MLR 82.03
- CGEM 21.79
About MLR Miller Industries Inc.
Miller Industries Inc is engaged in the manufacturing of vehicle towing and recovery equipment. The company produces wreckers, car carriers, and trailer bodies under the Century, Vulcan, Challenger, Holmes, Champion, Chevron, Eagle, Titan, Jige, and Boniface brands. The products are sold in North America, Canada, and Mexico through independent distributors.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.